GEN's A-List has Mounjaro nearly doubling and passing Ozempic, while Zepbound grew 174.9% to take the No. 10 spot and Wegovy landed at No. 11.
Recap by typeshit. Full story at qz.com.
Volume rose 53% while prices dropped, a sign cheaper access is pulling in patients. Breakdown covers LillyDirect pricing, the $50 Medicare Bridge and Novo's 2027 cuts.
Korea's first homegrown GLP-1 obesity drug, efpeglenatide, comes in about 25% below Wegovy and 40% below Mounjaro for its first four weeks.
MedPage Today
She's screened for diabetes at a BMI of 23 but denied a GLP-1 until 30. She argues insurers should use ethnicity-adjusted thresholds that guidelines already publish.
Pharmacist Paige notes the second round of Medicare drug price negotiation starts January 1, 2027, with the semaglutide family on the list.
Post hoc REDEFINE 1 data shown at The Menopause Society meeting found Novo's combo worked before, during and after menopause, with Mayo's Maria Hurtado Andrade urging caution.
University of Pretoria researchers found the 16-amino-acid peptide hit all 12 strains tested with low toxicity to mammalian cells. Wound stability is the next big hurdle.
Loading…